Major drugmakers were trading sharply lower on Tuesday as Wall Street is bracing for a broader set of tariffs that President ...

Pharma stocks just got a new risk factorand it's not a new drug trial. President Trump is preparing to slap tariffs on ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Pfizer delayed the announcement of its COVID-19 vaccine until after the 2020 election when it thought Donald Trump was ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 10.67%, which has investors questioning if this is right time ...

Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's success in 2020 ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Trump has claimed the company delayed an announcement for its vaccine until after the 2020 presidential election.

Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...